Automatic Web Traffic Generator

Arrowhead Pharmaceuticals Could Become The Next Gilead

Currently, there is no FDA approved cure for HBV infections, but Arrowhead Pharmaceuticals released data that suggests that they might have found one. The HBV market is a massive one, making the stock ... read more

Here's Why Arrowhead Pharmaceuticals Skyrocketed Almost 30% in September

Arrowhead Pharmaceuticals ... with a higher dose, it could be a problem. The study also tested 300 mg and 400 mg doses, which will be presented at the annual meeting of the American Association for th... read more

Janssen and Arrowhead strike $3.7bn RNAi deal

Janssen has struck a deal with Arrowhead Pharmaceuticals ... that allows hepatitis B to become established in the body, gaining exclusive worldwide rights to develop and market ARO-HBV, a subcutaneous ... read more

Arrowhead’s Future Could Now Ride on Progress of Amgen Partnership

Arrowhead Pharmaceuticals has nothing left in clinical trials. But a separate partnership with another biotech company, Amgen, could signal where Arrowhead goes next. The strategy shift became necessa... read more

Arrowhead Surges Forward With Major Deal And Its Intentions Were Highly Misunderstood

Arrowhead Pharmaceuticals establishes partnership deal with Johnson & Johnson for its Hepatitis B product in a deal that could potentially be worth up ... Two that come to mind would be those from Gil... read more

Forget Gilead Sciences: Intercept Pharmaceuticals, Inc. Is a Better Growth Stock

Gilead Sciences ... but one that could pay off handsomely if Ocaliva does become the first approved NASH treatment. Aggressive growth investors, in turn, might want to start grabbing shares ahead of O... read more

Arrowhead Stock Is Not Done Rallying After Its 38% Jump

revenue could potentially grow 53% annually, compared to the biotech average of 18.5%. On the stock market, Arrowhead stock’s rally is even more impressive because the iShares Nasdaq Biotechnology ETF ... read more

Novel Thyroid Beta Receptor Agonist Cut LDL-C in NAFLD Patients

Loomba disclosed support from Gilead, Merck, Intercept, NuSirt, Genfit, Promedior, Kinemed, Adheron, Allergan, Immuron, Galmed, Intercept, Arisaph, Shire, BMS, Galectin, Immuron, NGM, Siemens, Eli Lil... read more

Greater interest in the biotech sector

Next-generation drugs offer a host ... of significant growth for RNA-based drugs that could transform the drug industry. Janssen’s recently announced huge investment in Arrowhead Pharmaceuticals’ RNAi ... read more

Gilead pushes on with NASH drug after phase 2 success

Drugs approved in this indication could bring in billions ... treatment and is expected to become the leading cause of liver transplants within the next decade. Gilead said it will continue ... read more

Better Buy: Intercept Pharmaceuticals Inc. vs. Madrigal Pharmaceuticals

But that could change soon. Intercept Pharmaceuticals Inc. (NASDAQ ... study evaluating Ocaliva in treating NASH should be available in the first half of 2019. Gilead Sciences appears likely to be the ... read more